Special Communication
July 2014

Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical LiteratureA Cross-Sectional Analysis

Author Affiliations
  • 1Student, Yale University School of Medicine, New Haven, Connecticut
  • 2student, The Mayo Medical School, Mayo Clinic, Rochester, Minnesota
  • 3Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut
  • 4The Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine, New Haven, Connecticut
  • 5Section of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut
  • 6Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Connecticut
  • 7Division of Health Care Policy and Research, Mayo Clinic, Rochester, Minnesota
  • 8Section of General Internal Medicine, Yale University School of Medicine, New Haven, Connecticut

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2014;174(7):1176-1182. doi:10.1001/jamainternmed.2014.1371

The lipid component of the Action to Control Cardiovascular Risk in Diabetes (ACCORD-Lipid) trial was a landmark, publicly funded study demonstrating that fenofibrate, when added to statin therapy, was not associated with improved cardiovascular outcomes among patients with diabetes mellitus. We performed a cross-sectional study of all articles describing the results of ACCORD-Lipid in the news and biomedical literature in the 15 months following its publication. For articles published in biomedical journals, we determined whether there was an association between authors’ conflicts of interest and trial interpretation. We identified 67 news articles and 141 biomedical journal articles discussing ACCORD-Lipid. Approximately 30% of news and biomedical journal articles described fenofibrate as ineffective, whereas nearly 20% concluded it was effective. Among articles making a recommendation, approximately 50% of news and 67% of biomedical journal articles supported continued fibrate use. Authors with conflicts of interest were more likely to describe fenofibrate as effective (27.1% vs 8.9%; relative risk, 3.03; 95% CI, 1.22-7.50; P = .008) and support continued fibrate use (77.4% vs 45.8%; 1.69; 1.07-2.67; P = .006). The ACCORD-Lipid trial was described inconsistently in news and biomedical journal articles, possibly creating uncertainty among patients and physicians. In addition, conflicts of interest were associated with more favorable trial interpretation.